Evidence map›Paper›PMID 40603652›Full record

SynthesisLeukemia2025

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Vassilis Koutoulidis, Maria Trapali, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ioannis Ntanasis-Stathopoulos *Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-6328-9783
Charalampos Filippatos *Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis MalandrakisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Vassilis KoutoulidisFirst Department of Radiology, School of Medicine, Areteion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maria TrapaliLaboratory of Chemistry, Biochemistry and Cosmetic Science, Department of Biomedical Medicine, University of West Attica, Egaleo, Greece.
Efstathios KastritisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8191-5832
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-5133-1422
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8990-3254
Maria GavriatopoulouDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. mgavria@med.uoa.gr.ORCID 0000-0002-6244-1229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis and are traditionally deemed as "high-risk". However, in the setting of relapsed/refractory multiple myeloma (RRMM) their effect is less characterized. A systematic search was conducted in the PubMed database (end-of-search: 20 August 2024) for randomized controlled trials on anti-myeloma therapies for RRMM that reported outcomes for standard-risk and high-risk patient subgroups. A total of 28 studies were included; 23 reported progression-free survival (PFS) and 8 overall survival (OS) outcomes. Per overall analysis, high-risk cytogenetics were not associated with impaired treatment efficacy compared to standard-risk in terms of both PFS and OS. Among 9 treatment subgroups, high-risk patients on anti-BCMA therapies seemed to exhibit a 18% lower risk of a PFS event compared to the overall treatment effect for this population, but results were not significant. In the subgroup analyses, deletion 17p seemed to have the biggest impact on treatment efficacy, but results were not statistically significant. Overall, the presence of high-risk cytogenetics at study entry in RRMM did not alter treatment efficacy. Novel tools are needed to improve risk stratification at myeloma relapse.

Indexed as

Chromosome AberrationsMultiple MyelomaNeoplasm Recurrence, LocalChromosome DeletionCytogenetic AnalysisHumansPrognosisRandomized Controlled Trials as TopicTranslocation, GeneticTreatment Outcome

Identifiers

PMID40603652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.